This Phase 1 study is designed to determine the photoirritation potential of PEP005 Gel, 0.01% when application is followed by light exposure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
PEP005 (ingenol mebutate) Gel, 0.01%
TKL Research, Inc.
Paramus, New Jersey, United States
To determine the photoirritation potential of PEP005 Gel, when application is followed by light exposure.
Time frame: 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.